Overall Status

Recruiting (15)

Active, not recruiting (4)

Completed (3)

Terminated (3)

Not yet recruiting (2)

Suspended (1)

Unknown status (1)

Phase

phase 1 (12)

phase 2 (9)

phase 1/phase 2 (5)

early phase 1 (1)

n/a (1)

phase 3 (1)

Study Documents

Intervention Type

drug (22)

biological (16)

other (4)

procedure (3)

radiation (3)

combination product (1)

genetic (1)

Funder Type

Other (25)

Industry (4)

Study Type

Interventional (29)

Refractory Acute Lymphoblastic Leukemia

Showing 26 - 29 of 29

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

CD22 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Houston (Inotuzumab

Terminated

Has Results

CD22 Positive
+2 more

Inotuzumab Ozogamicin

Houston, Texas

M D Anderson Cancer Center

Mar 17, 2021

Refractory Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Moscow (Preparative regimen)

Recruiting

Refractory Acute Myeloid Leukemia
Refractory Acute Lymphoblastic Leukemia

Preparative regimen

Moscow, Russian Federation

Dmitry Rogachev National Research Center of Pediatric Hematology

Nov 19, 2020

Relapsed Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Refractory Acute Lymphoblastic Leukemia Trial in

Terminated

Relapsed Lymphoblastic Leukemia
+3 more

Sirolimus

Cincinnati, Ohio

Cincinnati Children's Hospital Medical Center

Sep 10, 2020

Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Shenzhen (CD19 CART)

Unknown status

Relapsed Acute Lymphoblastic Leukemia
Refractory Acute Lymphoblastic Leukemia

CD19 CART

Shenzhen, China

Shenzhen University General Hospital

Jul 7, 2019